2 terminated, 1 completed, 1 not yet recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 2, Completed 1, Not yet recruiting 1 |
Follow PAH: new trials by email Literature Review of PAH trials Research Report on PAH
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sota-ES - Sotatercept in Patients With Congenital Heart Disease and Eisenmenger´s Syndrome Sotatercept - Congenital Heart Disease (CHD), Eisenmenger Syndrome | Phase 2 | Not yet recruiting | Philipps University Marburg | 40 | 2026-09-01 | 2026-03-27 |
| CXA-10 Study in Subjects With Pulmonary Arterial Hypertension CXA-10 - PAH | Phase 2 | Terminated | Complexa, Inc. | 33 | 2019-08-09 | 2020-08-26 |
| PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH) 75mg CXA-10, 150mg CXA-10, Placebo - PAH | Phase 2 | Terminated | Complexa, Inc. | 69 | 2018-08-01 | 2020-08-10 |
| Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years oral treprostinil - PAH | Phase 2 | Completed | United Therapeutics | 32 | 2014-12-18 | 2025-03-30 |
Cardiovascular Diseases (2) · Connective Tissue Diseases (2) · Familial Primary Pulmonary Hypertension (2) · Hypertension (2) · Hypertension, Pulmonary (2) · Lung Diseases (2) · Pulmonary Arterial Hypertension (2) · Vascular Diseases (2) · Eisenmenger Complex (1) · Heart Defects, Congenital (1)
Respiratory Tract Diseases (2) · Skin and Connective Tissue Diseases (2) · Cardiovascular Abnormalities (1) · Cardiovascular Diseases (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Heart Diseases (1)
CXA-10 (2) · ACE-011 (1) · treprostinil (1)
Complexa, Inc. (2) · Philipps University Marburg (1) · United Therapeutics (1)
United States (3) · United Kingdom (2)
Theo Danoff, MD (2) · Dunbar Ivy, MD (1) · Stephan Rosenkranz, Prof. Dr. (1)